Literature DB >> 16751805

Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.

A Saxena1, C J Rorie, D Dimitrova, Y Daniely, J A Borowiec.   

Abstract

Nucleolin is a c-Myc-induced gene product with defined roles in ribosomal RNA processing and the inhibition of chromosomal DNA replication following stress. Here we find that changes in nucleolin protein levels in unstressed cells cause parallel changes in the amount of p53 protein. Alterations in p53 levels arise from nucleolin binding to the p53 antagonist Hdm2, resulting in the inhibition of both p53 ubiquitination and Hdm2 auto-ubiquitination. Nucleolin does not alter p53 ubiquitination by human papillomavirus E6, indicating that the effect is specific for Hdm2. Although the inhibition of ligase activity would be expected to stabilize Hdm2, we instead find that nucleolin also reduces Hdm2 protein levels, demonstrating that nucleolin inhibits Hdm2 using multiple mechanisms. Increases in nucleolin levels in unstressed cells led to higher expression of p21(cip1/waf1), a reduced rate of cellular proliferation, and an increase in apoptosis. Thus, nucleolin has a number of properties in common with the tumor suppressor ARF (alternate reading frame). We propose that nucleolin, like ARF, responds to hyperproliferative signals by upregulation of p53 through Hdm2 inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751805     DOI: 10.1038/sj.onc.1209714

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  The Nucleolus Takes Control of Protein Trafficking Under Cellular Stress.

Authors:  Narasimharao Nalabothula; Fred E Indig; France Carrier
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Over Expression of Nucleophosmin and Nucleolin Contributes to the Suboptimal Activation of a G2/M Checkpoint in Ataxia Telangiectasia Fibroblasts.

Authors:  Narasimharao Nalabothula; Devulapalli Chakravarty; Adam Pierce; France Carrier
Journal:  Mol Cell Pharmacol       Date:  2010

3.  PAF53 is essential in mammalian cells: CRISPR/Cas9 fails to eliminate PAF53 expression.

Authors:  Lawrence I Rothblum; Katrina Rothblum; Eugenie Chang
Journal:  Gene       Date:  2016-12-29       Impact factor: 3.688

4.  Nucleolin maintains embryonic stem cell self-renewal by suppression of p53 protein-dependent pathway.

Authors:  Acong Yang; Guilai Shi; Chenlin Zhou; Rui Lu; Hui Li; Lei Sun; Ying Jin
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

5.  Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2.

Authors:  Mu-Shui Dai; Xiao-Xin Sun; Hua Lu
Journal:  Mol Cell Biol       Date:  2008-04-21       Impact factor: 4.272

6.  RNA content in the nucleolus alters p53 acetylation via MYBBP1A.

Authors:  Takao Kuroda; Akiko Murayama; Naohiro Katagiri; Yu-mi Ohta; Etsuko Fujita; Hiroshi Masumoto; Masatsugu Ema; Satoru Takahashi; Keiji Kimura; Junn Yanagisawa
Journal:  EMBO J       Date:  2011-02-04       Impact factor: 11.598

7.  [Effect of nucleolin silencing on differentiation of rat neural stem cells in vitro and the molecular mechanism].

Authors:  Chong-Feng Chen; Huai-Cai Yang; Guo-Sheng Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

8.  Nucleolin stabilizes Bcl-X L messenger RNA in response to UVA irradiation.

Authors:  Jack Zhang; George Tsaprailis; G Tim Bowden
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

9.  Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation.

Authors:  Mikael S Lindström; Monica Nistér
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

10.  Stat1 nuclear translocation by nucleolin upon monocyte differentiation.

Authors:  Uwe Jerke; Sergey Tkachuk; Julia Kiyan; Victoria Stepanova; Angelika Kusch; Michael Hinz; Rainer Dietz; Hermann Haller; Bianca Fuhrman; Inna Dumler
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.